Evidence map›Paper›PMID 25734389›Full record

ArticleBritish journal of cancer2015

Stage at diagnosis and early mortality from cancer in England.

S McPhail, S Johnson, D Greenberg, M Peake, B Rous

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05876676 (Rapid Diagnostic Centre Biomarker Study), which is not on this map. Cited by 154 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
154citing papers in PubMed, 10 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05876676 recruitingnot on this mapstarted 2023, after this paper: background citation

Rapid Diagnostic Centre Biomarker Study

Typeobservational_patient_registrySponsorRoyal Marsden NHS Foundation TrustRan2023 to 2032Enrolled1,000ConditionsCancer
3 · Its place in the literature

Who cites it

154 citing papers in PubMed, 10 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Article
  15. Article
  16. Sex Differences in Cancer Stage at Diagnosis of Nonreproductive Solid Organ Tumors in the United States, 2015 to 2022.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026
    Article
  17. Article
  18. Article
  19. Article
  20. Article

94 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

S McPhailNational Cancer Intelligence Network (NCIN), Public Health England, 5th Floor, Wellington House, 135-155 Waterloo Road, London SE1 8UG, UK.
S JohnsonNational Cancer Intelligence Network (NCIN), Public Health England, 5th Floor, Wellington House, 135-155 Waterloo Road, London SE1 8UG, UK.
D GreenbergNational Cancer Registration Service (NCRS), Public Health England, Unit C, Magog Court, Shelford Bottom, Hinton Way, Cambridge CB22 3AD, UK.
M PeakeNational Cancer Intelligence Network (NCIN), Public Health England, 5th Floor, Wellington House, 135-155 Waterloo Road, London SE1 8UG, UK.
B RousNational Cancer Registration Service (NCRS), Public Health England, Unit C, Magog Court, Shelford Bottom, Hinton Way, Cambridge CB22 3AD, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundStage at diagnosis is a key predictor of overall cancer outcome. For the first time, stage completeness is high enough for robust analysis for the whole of England.

methodsWe analysed data from the National Cancer Registration Service's (NCRS) Cancer Analysis System on persons diagnosed with breast, colorectal, lung, prostate or ovarian cancers in England in 2012. One-year relative survival (followed-up to the end of 2013) was calculated along with adjusted excess rate ratios, for mortality within 1 year.

resultsOne-year relative survival decreased with increasing stage at diagnosis. For breast, prostate and colorectal cancers survival showed a major reduction for stage 4 cancers, whereas for lung and ovarian cancers there were substantial decreases in relative survival for each level of increase in stage. Excess rate ratios for mortality within 1 year of diagnosis showed that stage and age were the most important cofactors, but they also identified the statistically significant effects of sex, income deprivation and geographic area of residence.

conclusionsFurther reductions in mortality may be most effectively achieved by diagnosing all cancers before they progress to stage 4, but for lung and ovarian cancers there is also a need for a stage shift to earlier stages together with efforts to improve stage-specific survival at all stages.

Indexed as

Neoplasm StagingRegistriesAdolescentAdultAgedAged, 80 and overBreast NeoplasmsCohort StudiesColorectal NeoplasmsEarly Detection of CancerEnglandFemaleHumansLung NeoplasmsMaleMiddle Aged

Identifiers

PMID25734389
PMCPMC4385983

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.